

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this document, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this document.



維奧醫藥控股有限公司
Vital Pharmaceutical Holdings Limited

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 1164)

PROFIT WARNING

This announcement is made by the Company pursuant to Rule 13.09(1) of the Listing Rules.

The Board announces that the profits of the Group for the second half of year 2009 are expected to record a substantial decrease when compared to the corresponding period in 2008, due to the uncertainties of renewal import drug license of Osteoform.

Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.

The announcement is made by Vital Pharmaceutical Holdings Limited (the “**Company**”, together with its subsidiaries as the “**Group**”) pursuant to Rule 13.09(1) of the Rules (the “**Listing Rules**”) Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

The Board of directors (the “**Board**”) announces that the profits of the Group for the second half of year 2009 are expected to record a substantial decrease when compared to the corresponding period in 2008, due to the uncertainties of renewal import drug license of the Group’s major pharmaceutical product, Osteoform calcium amino acid chelate capsule (“**Osteoform**”). Shareholders can refer to the announcement of the Company dated 12 March 2009 which has disclosed the reason for such uncertainties. The Group had suspended the packing process of Osteoform temporarily. Also, as stated in the 2009 interim report of the Company, inventory of Osteoform had been sold out in the third quarter of 2009. Therefore, the turnover and profits of the Group for the second half of year 2009 are expected to record a substantial decrease when compared to the corresponding period in 2008.

The Company is in the process of preparing the final results of the Group for the year ended 31 December 2009. The information contained in this announcement is only based on the information currently available to the Company, and is not based on any figures or information that has been audited or reviewed by the Company’s auditors. Details of the Group’s performance will be disclosed as and when the final results for the year ended 31 December 2009 are announced.

Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
Vital Pharmaceutical Holdings Limited
Xu Xiaofan
Chairman

Hong Kong, 12 February 2010

As at the date of this announcement, the Board comprises six executive Directors: Mr. Xu Xiaofan, Mr. Chen Zhiyu, Madam Guo Lin, Mr. Huang Zemin, Mr. Li Ke and Mr. Liu James Jin, and three independent non-executive Directors: Mr. Lee Kwong Yiu, Mr. Lui Tin Nang and Mr. Chong Cha Hwa.